NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Wake Forest University Health Sciences
Conditions: Psoriasis
Interventions: Internet Survey
Countries: United States
Response to psoriasis treatment is variable in large part because of poor adherence treatments. Studies using electronic monitors have assessed adherence to topical and injectable psoriasis treatments and to biologics, yielding critically important insights. Adherence to oral psoriasis treatments is not as well characterized but is also critical, as the therapeutic windows for these treatments are narrower than for other psoriasis treatment options. The proposed study will assess patients' adherence to oral psoriasis treatment (primarily methotrexate) and will also collect pilot data on an intervention to improve adherence. The primary hypothesis of the investigators study is that adherence to oral psoriasis treatment is poor and that a reporting intervention may improve adherence to oral psoriasis treatment. In the investigator-blinded, 6-month prospective study, patients will be randomized to standard-of-care treatment or standard-of-care supplemented with the weekly online reporting intervention. Adherence will be assessed using electronic monitors. This randomized trial will permit the investigators to determine adherence to oral psoriasis treatment, assess the relationship between adherence and psoriasis outcomes, identify factors that are associated with adherence to oral psoriasis treatment (including physician trust, confidence in the treatment plan, and depression), and obtain preliminary data on the impact of an Internet-reporting measure on patients' adherence to oral psoriasis treatment .
Sex: ALL
Age: 12 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Any male or female 12 years or older of age with a diagnosis of psoriasis who is prescribed methotrexate by a dermatologist will be eligible for participation. * Greater than 10% of body surface involvement for psoriasis. * Subject is capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed. * The subject is able to complete the study and comply with study instructions, including attending all study visits. Exclusion Criteria: * Individuals younger than 12 years of age. * Known allergy or sensitivity to methotrexate. * Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access. * Introduction of any other prescription medication, topical or systemic, for psoriasis while participating in the study.
- Winston-Salem, North Carolina, United States